Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial
Cancer Communications2024Vol. 44(10), pp. 1214–1227
Citations Over TimeTop 1% of 2024 papers
Yan Zheng, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qin, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu, Quanli Gao, Peng Li, Zongfei Wang, Shilei Liu, Jianping Zhu, Haoran Wang, Haibo Ma, Zhenzhen Liu, Fei Zhao, Jun Zhang, Jun Zhang, He Zhang, Daoyuan Wu, Jinrong Qu, Jie Ma, Peng Zhang, Wenjie Ma, Ming Yan, Yongkui Yu, Qing Li, Jiangong Zhang, Jiangong Zhang, Wenqun Xing
Abstract
The interim results of this ongoing trial showed that in resectable ESCC, the addition of perioperative toripalimab to NAC is safe, may improve OS and might change the standard treatment in the future.
Related Papers
- → Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?(2014)43 cited
- → A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?(2015)1 cited
- [Is esophagectomy necessary for esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy].(2018)
- → Imaging Techniques for Detecting Complete Response after Neoadjuvant Therapy in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis(2020)
- → Impact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer(2020)